CD25/Interleukin-2Rα Chimeric Monoclonal Antibody (aa 116-122) (Basiliximab)

CD25, also known as interleukin-2 receptor α (IL-2Rα), is a transmembrane glycoprotein.¹ It is composed of two domains, D1 and D2, and associates with the CD122/IL-2β and CD132/IL-2γc subunits to form the heterotrimeric IL-2 receptor. CD25 is expressed in activated T and B cells, regulatory T cells, and lymphokine-activated killer (LAK) cells.^2,3,4 Activation of IL-2R on T cells increases the expression of CD25 and leads to T cell proliferation and differentiation, as well as activation-induced T cell death.^3,4 ILR2A expression and CD25 protein levels in bone marrow are increased in patients with acute myeloid leukemia (AML) and associated with poor prognosis.³ SNPs in ILR2A and elevated serum levels of a soluble form of CD25 are associated with an increased risk of Graves' disease.⁵ Cayman's CD25/Interleukin-2Rα Chimeric Monoclonal Antibody (aa 116-122) (Basiliximab) was produced recombinantly from the original human-murine chimeric antibody and can be used for flow cytometry (FC), immunofluorescence (IF), immunohistochemistry (IHC), and Western blot (WB). The original antibody was generated by fusing human IgG1κ constant domains to the antigen-binding domain of a mouse anti-CD25 monoclonal antibody, which targets the ERIYHV peptide corresponding to amino acids 116 to 122 of human CD25.^6,7

WARNING This product is not for human or veterinary use.

1. Stauber, D.J., Debler, E.W., Horton, P.A., et al. Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc. Natl. Acad. Sci. USA 103(8), 2788-2793 (2006).

2. Volkó, J., Kenesei, Á., Zhang, M., et al. IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2Rα therapies. Proc. Natl. Acad. Sci. USA 116(42), 21120-21130 (2019).

3. Li, J., Ran, Q., Xu, B., et al. Role of CD25 expression on prognosis of acute myeloid leukemia: A literature review and meta-analysis. PLoS One 15(7), e0236124 (2020).

4. Waldmann, T.A. The IL-2/IL-2 receptor system: A target for rational immune intervention. Immunol. Today 14(6), 264-270 (1993).

5. Lee, H.J., Li, C.W., Hammerstad, S.S., et al. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J. Autoimmun. 64, 82-90 (2015).

6. Kovarik, J., Wolf, P., Cisterne, J.M., et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 64(12), 1701-1705 (1997).

7. Binder, M., Vögtle, F.-N., Michelfelder, S., et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 67(8), 3518-3523 (2007).